AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Clin Infect Dis. 2021 Dec 6;73(11):e3677-e3689. doi: 10.1093/cid/ciaa1470.
There is limited understanding of the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization in Japan.
This study included 2638 cases enrolled from 227 healthcare facilities that participated in the COVID-19 Registry Japan (COVIREGI-JP). The inclusion criteria for enrollment of a case in COVIREGI-JP are both (1) a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test and (2) inpatient treatment at a healthcare facility.
The median age of hospitalized patients with COVID-19 was 56 years (interquartile range [IQR], 40-71 years). More than half of cases were male (58.9%, 1542/2619). Nearly 60% of the cases had close contact to confirmed or suspected cases of COVID-19. The median duration of symptoms before admission was 7 days (IQR, 4-10 days). The most common comorbidities were hypertension (15%, 396/2638) and diabetes without complications (14.2%, 374/2638). The number of nonsevere cases (68.2%, n = 1798) was twice the number of severe cases (31.8%, n = 840) at admission. The respiratory support during hospitalization includes those who received no oxygen support (61.6%, 1623/2636) followed by those who received supplemental oxygen (29.9%, 788/2636) and invasive mechanical ventilation/extracorporeal membrane oxygenation (8.5%, 225/2636). Overall, 66.9% (1762/2634) of patients were discharged home, while 7.5% (197/2634) died.
We identified the clinical epidemiological features of COVID-19 in hospitalized patients in Japan. When compared with existing inpatient studies in other countries, these results demonstrated fewer comorbidities and a trend towards lower mortality.
对于需要住院治疗的 2019 冠状病毒病(COVID-19)患者在日本的特征,目前了解有限。
本研究纳入了来自参与 COVID-19 注册研究日本(COVIREGI-JP)的 227 家医疗机构的 2638 例病例。COVIREGI-JP 纳入病例的标准为:(1)SARS-CoV-2 检测阳性,(2)住院治疗于医疗机构。
COVID-19 住院患者的中位年龄为 56 岁(四分位间距 [IQR],40-71 岁)。超过一半的病例为男性(58.9%,1542/2619)。将近 60%的病例与确诊或疑似 COVID-19 病例有密切接触。住院前症状的中位持续时间为 7 天(IQR,4-10 天)。最常见的合并症是高血压(15%,396/2638)和无并发症的糖尿病(14.2%,374/2638)。非重症病例(68.2%,n=1798)的数量是重症病例(31.8%,n=840)的两倍。住院期间的呼吸支持包括未接受氧支持(61.6%,1623/2636)、接受补充氧(29.9%,788/2636)和有创机械通气/体外膜肺氧合(8.5%,225/2636)。总体而言,2634 例患者中有 66.9%(1762/2634)出院回家,7.5%(197/2634)死亡。
我们确定了日本 COVID-19 住院患者的临床流行病学特征。与其他国家现有的住院研究相比,这些结果显示合并症较少,死亡率呈下降趋势。